Nutcracker Therapeutics, Inc. Sustainability Profile
Nutcracker Therapeutics, Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative RNA therapeutics. Founded in 2015, the company has rapidly established itself within the biopharmaceutical industry, focusing on harnessing the power of RNA to create transformative treatments for various diseases. With a unique platform that enables the precise delivery of RNA molecules, Nutcracker Therapeutics aims to address unmet medical needs in areas such as oncology and rare genetic disorders. The company’s commitment to advancing RNA-based therapies has positioned it as a notable player in the market, attracting attention for its cutting-edge research and development initiatives. As it continues to expand its operational reach, Nutcracker Therapeutics remains dedicated to improving patient outcomes through its groundbreaking therapeutic solutions.
DitchCarbon Score
How does Nutcracker Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nutcracker Therapeutics, Inc.'s score of 25 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nutcracker Therapeutics, Inc.'s reported carbon emissions
In 2023, Nutcracker Therapeutics, Inc. reported total carbon emissions of approximately 38,871 kg CO2e for Scope 1 and about 3,059 kg CO2e for Scope 2. This marks a reduction from 2022, where emissions were approximately 40,553 kg CO2e for Scope 1 and 4,937 kg CO2e for Scope 2. The company has demonstrated a commitment to reducing its carbon footprint, although no specific reduction targets or initiatives have been disclosed. Nutcracker Therapeutics has not reported any Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. The absence of cascaded data suggests that the emissions figures are independently reported without influence from a parent organisation. Overall, while Nutcracker Therapeutics, Inc. has made strides in reducing its emissions, further transparency regarding climate commitments and reduction strategies would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 40,553 | 00,000 |
| Scope 2 | 4,937 | 0,000 |
| Scope 3 | - | - |
How Carbon Intensive is Nutcracker Therapeutics, Inc.'s Industry?
How Carbon Intensive is Nutcracker Therapeutics, Inc.'s Location?
Nutcracker Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Nutcracker Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
